Terms: = Endocrine gland cancer AND ECT2L, 345930, C6orf91, Q008S8, LFDH, dJ509I19_3, dJ509I19_2, ENSG00000203734 AND Treatment
40124 results:
1. Deciphering the progression of fine-needle aspiration: A bibliometric analysis of thyroid nodule research.
Liu T; Yang F; Qiao J; Mao M
Medicine (Baltimore); 2024 May; 103(20):e38059. PubMed ID: 38758913
[TBL] [Abstract] [Full Text] [Related]
2. Palliative treatment of generalized metastatic follicular carcinoma of thyroid after operation: A case report and literature review.
Zhao H; Kang W; Guan J; Wang Y
Medicine (Baltimore); 2024 May; 103(20):e38237. PubMed ID: 38758843
[TBL] [Abstract] [Full Text] [Related]
3. Genome-wide loss of heterozygosity predicts aggressive, treatment-refractory behavior in pituitary neuroendocrine tumors.
Lin AL; Rudneva VA; Richards AL; Zhang Y; Woo HJ; Cohen M; Tisnado J; Majd N; Wardlaw SL; Page-Wilson G; Sengupta S; Chow F; Goichot B; Ozer BH; Dietrich J; Nachtigall L; Desai A; Alano T; Ogilive S; Solit DB; Bale TA; Rosenblum M; Donoghue MTA; Geer EB; Tabar V
Acta Neuropathol; 2024 May; 147(1):85. PubMed ID: 38758238
[TBL] [Abstract] [Full Text] [Related]
4. Current data and future perspectives on DNA methylation in ovarian cancer (Review).
Fu M; Deng F; Chen J; Fu L; Lei J; Xu T; Chen Y; Zhou J; Gao Q; Ding H
Int J Oncol; 2024 Jun; 64(6):. PubMed ID: 38757340
[TBL] [Abstract] [Full Text] [Related]
5. Intelligent nanovesicle for remodeling tumor microenvironment and circulating tumor chemoimmunotherapy amplification.
Huai M; Wang Y; Li J; Pan J; Sun F; Zhang F; Zhang Y; Xu L
J Nanobiotechnology; 2024 May; 22(1):257. PubMed ID: 38755645
[TBL] [Abstract] [Full Text] [Related]
6. Niraparib, Dostarlimab, and Bevacizumab as Combination Therapy in Pretreated, Advanced Platinum-Resistant Ovarian cancer: Findings From Cohort A of the OPAL Phase II Trial.
Liu JF; Gaillard S; Wahner Hendrickson AE; Yeku O; Diver E; Gunderson Jackson C; Arend R; Ratner E; Samnotra V; Gupta D; Chung J; Zhang H; Compton N; Baines A; Bacqué E; Liu X; Felicetti B; Konecny GE
JCO Precis Oncol; 2024 May; 8():e2300693. PubMed ID: 38754056
[TBL] [Abstract] [Full Text] [Related]
7. Feasibility and cost-effectiveness of genetic counselling for all patients with newly diagnosed ovarian cancer: a single-centre retrospective study.
Schlootz S; Saner FAM; Rabaglio M; Imboden S; Wampfler J
Swiss Med Wkly; 2024 Apr; 154():3386. PubMed ID: 38754016
[TBL] [Abstract] [Full Text] [Related]
8. Rare Columnar Cell Variant of Papillary Thyroid Carcinoma with Cervical Spine Metastasis: A Case Report.
Yu J; Yang G; Oh HY; Ryu YJ
Curr Med Imaging; 2024; 20(1):e15734056300884. PubMed ID: 38752631
[TBL] [Abstract] [Full Text] [Related]
9. Trends and projections of the global burden of thyroid cancer from 1990 to 2030.
Hu S; Wu X; Jiang H
J Glob Health; 2024 May; 14():04084. PubMed ID: 38751316
[TBL] [Abstract] [Full Text] [Related]
10. Identification of necroptosis-related gene signatures for predicting the prognosis of ovarian cancer.
Qin Y; Sheng Y; Ren M; Hou Z; Xiao L; Chen R
Sci Rep; 2024 May; 14(1):11133. PubMed ID: 38750159
[TBL] [Abstract] [Full Text] [Related]
11. Safety and efficacy of peptide receptor radionuclide therapy in neuroendocrine tumors: A single center experience.
Sukrithan V; Armbruster H; Rogers S; Vogt SM; Grenade C; Verschraegen C; Zhou Y; Goyal A; Natwa M; Hussein A; Barr H; Konate D; Batdorf R; Brown A; Williams B; Zhao S; Wei L; Xu M; Shah MH; Konda B
PLoS One; 2024; 19(5):e0298824. PubMed ID: 38748739
[TBL] [Abstract] [Full Text] [Related]
12. Shikonin reduces M2 macrophage population in ovarian cancer by repressing exosome production and the exosomal galectin 3-mediated β-catenin activation.
Wang M; Sun Y; Gu R; Tang Y; Han G; Zhao S
J Ovarian Res; 2024 May; 17(1):101. PubMed ID: 38745186
[TBL] [Abstract] [Full Text] [Related]
13. The Role of Palliative Surgery in the Management of Acute Intestinal Obstruction Secondary to Peritoneal Carcinomatosis.
Bhat BK; Yadav A; Nundy S
Chirurgia (Bucur); 2024 Apr; 119(2):218-226. PubMed ID: 38743835
[No Abstract] [Full Text] [Related]
14. Differentially expressed genes associated with high metabolic tumor volume served as diagnostic markers and potential therapeutic targets for pancreatic cancer.
Kim BG; Lee SH; Jang Y; Kang S; Kang CM; Cho NH
J Transl Med; 2024 May; 22(1):453. PubMed ID: 38741142
[TBL] [Abstract] [Full Text] [Related]
15. [A rare cause of hypercorticism: ACTH-secreting pheochromocytoma (a case report)].
Rifai K; Toulali F; Iraqi H; Ettaik M; Gharbi MEH
Pan Afr Med J; 2024; 47():88. PubMed ID: 38737225
[TBL] [Abstract] [Full Text] [Related]
16. A Competing Risk Nomogram for Prediction of Prognosis in Patients With Primary Squamous Cell Thyroid Carcinoma.
Tian Y; He L; Zhang B; Deng L; Wang J
Technol Cancer Res Treat; 2024; 23():15330338241254059. PubMed ID: 38725285
[No Abstract] [Full Text] [Related]
17. Genomic Profiling of Rare Undifferentiated Sarcomatoid Subtypes of Pancreatic Carcinomas: In Search of Therapeutic Targets.
Faber EB; Krause HB; Amin K; Walker P; Hosein PJ; Shields AF; Lenz HJ; Prakash A; Goel S; Oberley M; Malleo G; Luchini C; Hwang J; Florou V; Garrido-Laguna I; Lou E
JCO Precis Oncol; 2024 May; 8():e2300595. PubMed ID: 38723231
[TBL] [Abstract] [Full Text] [Related]
18. Metabolomic screening of radioiodine refractory thyroid cancer patients and the underlying chemical mechanism of iodine resistance.
Zheng W; Tang X; Dong J; Feng J; Chen M; Zhu X
Sci Rep; 2024 May; 14(1):10546. PubMed ID: 38719979
[TBL] [Abstract] [Full Text] [Related]
19. [Analysis of factors affecting the prognosis of patients with pancreatic cancer patients with obstructive jaundice].
Zhang L; Li M; Sun QF; Yu HP
Zhonghua Nei Ke Za Zhi; 2024 May; 63(5):474-479. PubMed ID: 38715484
[No Abstract] [Full Text] [Related]
20. Overweight as a biomarker for concomitant thyroid cancer in patients with Graves' disease.
Park J; An S; Bae JS; Kim JS; Kim K
Front Endocrinol (Lausanne); 2024; 15():1382124. PubMed ID: 38711981
[TBL] [Abstract] [Full Text] [Related]
[Next]
